


Fundación de
Cáncer de Mama

OFFICIAL
best of
SABCS™



JUEVES
7/FEB

7:50 - 8:50		Desayuno con el experto: Cambiando la historia natural del cáncer de mama: ¿Dónde estamos y qué sigue para la enfermedad HER2-positivo y Triple Negativo?	Dra. Claudia Arce Salinas
9:00		Inauguración: Presentación de presidium	Dr. Pabel Miranda Aguirre.
9:20		GS3-01 A Randomized Placebo Controlled Phase III Trial of Low Dose Tamoxifen for the Prevention of Recurrence in Women with Operated Hormone Sensitive Breast Ductal or Lobular Carcinoma In Situ.	Dr. Carlos Domínguez Reyes.
9:35	Hormonotherapy	GS6-03 Symptoms and health-related quality of life on endocrine therapy alone versus chemoendocrine Therapy (C+E): TAILORx patient-reported outcomes results.	Dra. Alejandra Armengol Alonso
9:50		GS3-03 Effects of Prolonging adjuvant aromatase inhibitor Therapy Beyond Five years on Recurrence and Cause-specific mortality: An EBCTCG meta-analysis of individual patient data from 12 randomised trials including 24,912 women.	Dra. Ana Zempoalteca López
10:05		PALLET: A neoadjuvant study to compare the clinical and antiproliferative effects of letrozole with and without palbociclib. Dowsett	Dr. Alejandro Juárez Ramiro
10:20		Panel de discusión	Dr. Fernando Aldaco Sarvide
10:45		Secuencia de Quimioterapia en el Tratamiento del Cáncer de Mama Metastásico Her 2 Negativo: La importancia de la supervivencia global.	Dra. Maricela García
11:35		RECESO	
12:00	Local Therapy	GS6-1 Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women with Breast Cancer: Results from a Prospective Cohort Study	Dr. Julio Ramírez Bollas
12:15		ES11-3 Microsurgical treatment of lymphedema	Dr. Francisco Said Lemus
12:30		ES7-3 Indications for radiation treatments after neoadjuvant chemotherapy while awaiting the results of clinical trials	Dra. Abril Antonia Quezada B.
12:45		GS4-03 RAPID: A randomized trial of accelerated partial breast irradiation using 3-Dimensional conformal radiotherapy (3D-CRT)	Dr. Jorge Anselmo Vázquez D.
13:00		Panel de discusión	Dr. Enrique Bargalló Rocha
13:25		RECESO (Box lunch)	
13:50		GS2-03 Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients.	Dra. Paula Cabrera Galeana
14:05	Triple Negative	GS2-04 Efficacy Results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant Capecitabine after standard chemotherapy for patients with early triple negative breast cancer.	Dra. Laura Torrecillas Torres
14:20		GS2-05 Impact of the Delayed initiation of adjuvant chemotherapy in the outcomes of triple negative breast cancer.	Dr. Luis Alfonso Romero
14:35		GS5-06 No survival benefit of chemotherapy escalation in patients with pCR and "high-immune" triple-negative early breast cancer in the neoadjuvant WSG-ADAPT-TN trial. Gluz	Dra. Rocío Grajales Álvarez
14:50			Panel de discusión
15:15		CIERRE	



Fundación de
Cáncer de Mama

OFFICIAL
best of
SABCS™



VIERNES
8/FEB

7:50 - 8:50		Desayuno con el experto: Nab-paclitaxel en cáncer de mama: Estado actual y perspectivas.	Dr. Ricardo Villalobos Valencia
8:50		Presentación del día	Dra. Betsabé Hernández H.
9:00	Genetic	CS1-3 Moderate Penetrance Mutations: ¿What to do?	Dra. Silvia Vidal
9:15	HER2 Over-expressed	GS2-07 PHARE randomized trial final results comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer.	Dra. Perla Pérez Pérez
9:30		GS1-10 Phase III Study of Trastuzumab Emtansine (TDM1) vs Trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE.	Dra. Brenda Carbajal Saldaña
9:45		GS5-01 A randomized community-based trial of an angiotensin converting enzyme inhibitor, Lisinopril or a beta blocker, carvedilol for the prevention of cardiotoxicity in patients with early stage HER-positive breast cancer receiving adjuvant trastuzumab. Munster	Dra. Marytere Herrera Martínez
10:00		Panel de discusión	Dra. Guadalupe Cervantes S.
10:25		Simposio: "Conversación de expertos sobre nueva evidencia de palbociclib: Neoadyuvancia & SG".	Dra. Guadalupe Cervantes y Dra. Cinthya Villareal
11:15		RECESO	
11:40	Local Therapy Axilla	ES7-1 Methods to Minimize the False Negative Rate of Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy for Node Positive Breast Cancer .	Dr. Carlos Fernando Gómez
11:55		ES7-2 Practical Approach to the axilla after neoadjuvant chemotherapy: What the clinical trials dont address.	Dr. Jorge Enrique Monges
12:10		GS4-02 Regional Lymph Node irradiation in early stage breast cancer: an EBCTCG meta-analysis of 13,000 women in 14 trials.	Dr. Armando Félix Leyva
12:25		GS4-01 Radiotherapy or surgery of the axila after a positive sentinel node in breast cancer patients: 10 years follow up results of the EORTC. AMAROS Trial (EORTC 10981/22023)	Dr. Felipe Villegas Carlos
12:40		Panel de discusión	Dr. Gregorio Quintero Beuló
13:05		RECESO (Box lunch)	
13:30	Genomic	GS1-02 Towards a Human Breast Cell Atlas.	Dr. Alfredo Hidalgo Miranda
13:45	Metastatic	GS3-07 Clinical Utility of Circulating tumor cell count as a tool to chose between first line hormone therapy an chemotherapy for ER+ HER2- metastatic breast cancer: Results of the phase III STIC CTC trial.	Dr. Mario Escobar Gómez
14:00		GS3-08 Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial. Juric	Dr. Saúl Campos Gómez
14:15		GS1-04 Impassion 130: Efficacy in immune Biomarkers subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment naive, locally advanced or metastatic triple negative breast cancer	Dr. Ricardo Villalobos Valencia
14:30		Panel de discusión	Dra. Flavia Morales Vásquez
14:55		CLAUSURA / CANAPÉS	